Colonic hypereosinophilia in ulcerative colitis may help to predict the failure of steroid therapy
- PMID: 30535522
- DOI: 10.1007/s10151-018-1896-9
Colonic hypereosinophilia in ulcerative colitis may help to predict the failure of steroid therapy
Abstract
Background: Although glucocorticosteroids (GS) and mesalazine are effective and widely employed to treat moderate-to-severe ulcerative colitis (UC), information regarding the factors responsible for response to such therapy is still scarce. One of these factors is thought to be an increased number of mucosal eosinophils. The aim of our study was to determine whether the presence of hypereosinophilia in colonic mucosa of UC patients might influence the short-term response to l treatment with GS and mesasalazine.
Methods: Clinical, endoscopic, and pathologic data from patients with a recent diagnosis of moderate UC, who had not undergone treatment, were obtained, and the short-term outcome after 1 month of conventional first-line treatment (mesalazine plus GS) was evaluated.
Results: There were 53 patients with a median age of 37 years (95% CI 30-47).Overall, at the end of treatment period 16 (30%) patients responded, whereas a response was not observed in the other 37 (70%) patients. Interestingly, all patients of this latter group had colonic mucosal hypereosinophilia. No significant differences were found between the two groups concerning sex and age at diagnosis, but hypereosinophilia was inversely correlated with the duration of the disease (p = 0.054), and significantly correlated to the localization of UC (p = 0.0023). In addition, The Mayo score was significantly higher in patients with hypereosinophilia (median 8; 95% CI 8-9;) when compared to patients without hypereosinophilia (median 7; 95% CI 7-7, p < 0.0001) including the Mayo endoscopic subscore (median 3; 95% CI 2-3 vs median 2; 95% CI 2-2, respectively; p = 0.007).
Conclusions: The presence of colonic mucosal hypereosinophilia may be useful to predict the short-term outcome to conventional first-line therapy in treatment-naïve UC patients. It remains to be seen whether this might be important in modifying the first-line therapy in this subgroup of patients.
Keywords: Eosinophils; Intestinal Mucosa; Outcome; Treatment; Ulcerative colitis.
Similar articles
-
Severe eosinophilic infiltration in colonic biopsies predicts patients with ulcerative colitis not responding to medical therapy.Colorectal Dis. 2014 Dec;16(12):O420-30. doi: 10.1111/codi.12725. Colorectal Dis. 2014. PMID: 25040651
-
Effect of Long-Term Mesalamine Therapy on Cancer-Associated Gene Expression in Colonic Mucosa of Patients with Ulcerative Colitis.Dig Dis Sci. 2019 Mar;64(3):740-750. doi: 10.1007/s10620-018-5378-8. Epub 2018 Nov 26. Dig Dis Sci. 2019. PMID: 30478770
-
Mucosal Eosinophilia Is an Independent Predictor of Vedolizumab Efficacy in Inflammatory Bowel Diseases.Inflamm Bowel Dis. 2020 Jul 17;26(8):1232-1238. doi: 10.1093/ibd/izz251. Inflamm Bowel Dis. 2020. PMID: 31633167 Free PMC article.
-
Conventional therapy for moderate to severe inflammatory bowel disease: A systematic literature review.World J Gastroenterol. 2019 Mar 7;25(9):1142-1157. doi: 10.3748/wjg.v25.i9.1142. World J Gastroenterol. 2019. PMID: 30863001 Free PMC article.
-
The safety of beclomethasone dipropionate in the treatment of ulcerative colitis.Expert Opin Drug Saf. 2018 Sep;17(9):963-969. doi: 10.1080/14740338.2018.1510914. Epub 2018 Aug 21. Expert Opin Drug Saf. 2018. PMID: 30101623 Review.
Cited by
-
Eosinophils in the gastrointestinal tract and their role in the pathogenesis of major colorectal disorders.World J Gastroenterol. 2019 Jul 21;25(27):3503-3526. doi: 10.3748/wjg.v25.i27.3503. World J Gastroenterol. 2019. PMID: 31367153 Free PMC article. Review.
-
Histopathology of IBD Colitis. A practical approach from the pathologists of the Italian Group for the study of the gastrointestinal tract (GIPAD).Pathologica. 2021 Feb;113(1):39-53. doi: 10.32074/1591-951X-235. Pathologica. 2021. PMID: 33686309 Free PMC article. Review.
-
Hypereosinophilic Syndrome Secondary to Ulcerative Colitis and Primary Sclerosing Cholangitis.Case Rep Gastroenterol. 2023 Jan 10;17(1):41. doi: 10.1159/000527380. eCollection 2023 Jan-Dec. Case Rep Gastroenterol. 2023. PMID: 36742098 Free PMC article.
-
Eosinophils, Eosinophilic Gastrointestinal Diseases, and Inflammatory Bowel Disease: A Critical Review.J Clin Med. 2024 Jul 14;13(14):4119. doi: 10.3390/jcm13144119. J Clin Med. 2024. PMID: 39064159 Free PMC article. Review.
-
Prognostic Value of Colonic Tissue and Blood Eosinophils in Ulcerative Colitis.Inflamm Bowel Dis. 2023 Jan 5;29(1):62-69. doi: 10.1093/ibd/izac044. Inflamm Bowel Dis. 2023. PMID: 35275200 Free PMC article.
References
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical